<DOC>
	<DOC>NCT00616733</DOC>
	<brief_summary>This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.</brief_summary>
	<brief_title>12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis of clinically isolated syndrome or a relapsing form(s) of MS, based on Poser or McDonald criteria (may include patients with secondary progressive disease) Clinical relapse within the past 3 years or a gadolinium enhancing lesion on a brain MRI scan within the past 12 months Baseline EDSS score of 0 6.5 Female subjects who are sexually active, unless sterile or postmenopausal for at least 1 year, must be willing to use doublebarrier contraception Primary progressive MS Any medical condition that predisposes to immunocompromise History of malignancy, tuberculosis, invasive fungal infections, herpes zoster infection (or shingles), or other opportunistic infection, or any current active infection Concurrent diagnosis of any other autoimmune disease (eg, rheumatoid arthritis or lupus) Treatment with cyclophosphamide or mitoxantrone within 6 months of study initiation Treatment with cyclosporine, azathioprine, methotrexate or other immunosuppressant within 3 months of study initiation Treatment with interferon beta or glatiramer acetate within 2 months of study initiation Prior treatment with natalizumab or rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Multiple sclerosis, relapsing, secondary progressive, clinically isolated syndrome, MRI</keyword>
</DOC>